A 49-year-old Caucasian woman presented to the dermatology clinic for follow-up of malignant melanoma with a complaint of painless gross hematuria. Two years prior she was diagnosed with malignant melanoma from a skin lesion on her left flank treated with wide excision, negative axillary sentinel lymph node biopsy, and adjuvant radiotherapy. Subsequently, she had no evidence of disease until urologic evaluation of her hematuria revealed two lesions in her bladder and cytopathology demonstrated findings consistent with malignant melanoma. We review literature on melanoma metastatic to the bladder and discuss the potential role of metastasectomy and other treatment strategies in such rare cases.
Introduction
While melanoma represents the deadliest form of skin cancer, reported cases of metastasis to the bladder are rare, with just 29 confirmed cases reported in English-language literature. This number is likely an underestimation of the true burden of disease, as autopsy series of patients with metastatic melanoma have found an 18%e37% rate of metastatic disease to the bladder. 1, 2 Nonetheless, metastatic disease that presents in the bladder is rare and poses a significant challenge in diagnosis and management. We report a case that highlights such challenges and review literature on metastatic melanoma with a focus on bladder metastases.
Case presentation
A 49-year-old Caucasian woman presented to the dermatology clinic for follow-up of her malignant melanoma with a complaint of painless gross hematuria. Two years prior she was diagnosed with malignant melanoma from a skin lesion on her left flank. She had a wide excision with negative margins and a negative axillary sentinel lymph node biopsy. The pathology confirmed stage IIC (7 mm thickness, Clark level IV) malignant melanoma and she received 3000 cGy of adjuvant radiotherapy to the left flank. The patient had no evidence of disease until her presentation with hematuria. A computed tomography (CT) scan demonstrated two enhancing lesions in the bladder, with the largest one measuring 33 mm in largest diameter along the left posterolateral bladder wall ( Fig. 1A ). Voided urine cytology identified cells that expressed S-100, HMB-45, and Melan-A, consistent with malignant melanoma ( Fig. 2 ). Cystoscopy demonstrated a large nodular mass with brown pigmentation on the left trigone as well as multiple discontinuous nodular lesions on the left lateral wall ( Fig. 1B) . Although the remainder of her abdominal/pelvic CT was free of visible disease, a more thorough metastatic survey was completed, and brain magnetic resonance imaging demonstrated frontal and occipital lobe lesions consistent with metastatic disease. Given the multiple sites of metastatic disease, we felt the patient was not likely to derive a survival benefit from metastasectomy, which for complete resection in the location of her trigone would likely require cystectomy. She was treated conservatively with stereotactic body radiation therapy (SBRT) of the brain metastases, systemic therapy with checkpoint inhibitor Abbreviations: CT, computed tomography; MRI, magnetic resonance imaging; TURBT, transurethral resection of bladder tumor; TUR, transurethral resection; SBRT, stereotactic body radiation therapy.
Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
* Corresponding author. Fax: þ1 888 224 9048. E-mail address: vitaly.margulis@utsouthwestern.edu (V. Margulis).
Contents lists available at ScienceDirect
Urology Case Reports 
Discussion
Malignant melanoma is the deadliest skin cancer in the United States with over 67,000 new cases per year and an estimated 30% will eventually develop metastases. 3 While the majority of metastatic spread occurs to skin, lungs, liver, and brain, metastasis to the bladder in clinical series appear to be rare with only 29 reported cases in the literature (Table 1 ). This in contrast to autopsy series which indicate an 18%e37% incidence of metastatic disease in the bladder. 1, 2 The most common presenting symptom is hematuria, and isolated metastatic disease to the bladder is relatively rare. The confirmation of metastatic melanoma is made possible through immunohistochemical analysis demonstrating characteristic expression of S-100, HMB-45, MART-1/Melan-A, tyrosinase, and MITF.
Once metastatic, treatment options are limited and survival is generally poor, reflecting a lack of effective systemic therapies. Chemotherapeutics have limited effect on survival, however the introduction of immunotherapy has been promising in select cases. Interleukin-2 therapy was introduced in the late 1990s but with a low response rate and significant side effects including an inflammatory response syndrome that often limits treatment. Targeted therapies in the form of BRAF, MEK, KIT, VEGF pathway inhibitors have improved response rates, but not durably. More recent use of checkpoint inhibitors including antibodies targeting PD-1 or PD-L1 and CTLA4 are promising due to higher response rates and a chance of durable response. 4 Location of the initial metastatic site appears to be a significant predictor of survival with improved survival for skin metastases, and progressively lower survival associated with distant nodal involvement, gastrointestinal, lung, bone, liver, and brain metastasis. Given the few cases of bladder metastases reported in the literature, it is not clear if this location portends a worse outcome.
The question for urologists dealing with metastatic melanoma to the bladder is: does surgery play a role in the management, and if so, should management be transurethral resection (TUR) or cystectomy? Similar to genitourinary malignancies, metastasectomy for malignant melanoma is controversial, but retrospective data suggests metastasectomy may be associated with improved overall survival compared to systemic therapy alone. 5 The role of metastasectomy in the era of newer effective systemic agents is likely to be answered in future studies, but at present, a multidisciplinary team of surgeons, radiation oncologists, and medical oncologists should jointly devise a treatment strategy. In the other reported cases of metastatic melanoma to the bladder, treatment varied from observation, transurethral resection, and even cystectomy. The choice of surgical strategy should be based on overall prognosis, the patient's health status, presence of local symptoms attributable to bladder metastases, invasiveness of approach, and quality of life factors. Bladder metastases resulting in hematuria and voiding symptoms that can sometimes be managed by TUR, however TUR may not be sufficient to remove the entire tumor in many cases. Obviously, radical cystectomy or partial cystectomy for metastatic disease represents a markedly aggressive step compared to TUR, and such cases should probably be limited to those with solitary or limited metastatic disease and favorable prognostic factors. Unfortunately, our patient had concomitant brain metastasis and we felt there was limited evidence she would benefit from more invasive surgery. We elected to administer SBRT for her brain lesions, offer systemic therapy with combined checkpoint inhibitor immunotherapy, and manage her bladder metastasis conservatively.
Growing evidence suggests the efficacy of SBRT in melanoma, despite previous consideration that this tumor was 'radioresistant,' and possible synergistic effects of radiation with immunotherapy, the so-called 'abscopal effect.' 
Conclusion
Reported cases of metastatic melanoma to the bladder are rare. While long-term survival of patients with metastatic melanoma is rare, evolving treatment strategies and increasing acceptance of a survival benefit to metastasectomy in certain settings poses significant challenges to management. Integrating urologic treatments into a multidisciplinary strategy is important in managing these patients.
